CLINICAL TRIALS PROFILE FOR TOLTERODINE TARTRATE
✉ Email this page to a colleague
All Clinical Trials for Tolterodine Tartrate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00143377 ↗ | Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB | Completed | Pfizer | Phase 4 | 2004-09-01 | The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment. |
| NCT00143377 ↗ | Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | 2004-09-01 | The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment. |
| NCT00293839 ↗ | Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder | Completed | Alza Corporation, DE, USA | Phase 3 | 1969-12-31 | The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period. |
| NCT00444925 ↗ | Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB) | Completed | Pfizer | Phase 3 | 2007-04-01 | To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder |
| NCT00454740 ↗ | Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder | Completed | Astellas Pharma Inc | Phase 3 | 2004-06-01 | To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes |
| NCT00768521 ↗ | A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) | Completed | Merck Sharp & Dohme Corp. | Phase 1 | 2008-09-03 | This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted. |
| NCT00795509 ↗ | Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan). | Completed | Pfizer | 2007-08-01 | The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tolterodine Tartrate
Condition Name
Clinical Trial Locations for Tolterodine Tartrate
Trials by Country
Clinical Trial Progress for Tolterodine Tartrate
Clinical Trial Phase
Clinical Trial Sponsors for Tolterodine Tartrate
Sponsor Name
